Skip to main content
Premium Trial:

Request an Annual Quote

CardioDx Raises $60M in Private Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CardioDx today announced it has closed on a $60 million equity round.

The Palo Alto, Calif.-based cardiovascular genomics testing firm said that the funding will be used to expand reimbursement coverage in the US for its Corad CAD, a gene expression test to determine which patients have or don't have coronary artery disease. The test was launched in June 2009 as a laboratory-developed test.

New investors Longitude Capital, JP Morgan, Acadia Woods Partners, Artiman Ventures, and Bright Capital, the venture arm of RU-COM, participated in the round, which also included previous investors.

Prior investors in the firm include Kleiner, Perkins, Caufield & Byers; TPG Biotech; Mohr Davidow Ventures; Intel Capital; Pappas Ventures; DAG Ventures; Asset Management; and GE Capital.

David Levison, CardioDx's CEO, told GenomeWeb Daily News in March that the firm had raised more than $40 million in a Series E round and added that the company would hold a second closing on the round.

A company spokeswoman confirmed that the $60 million is the final figure on the Series E round.

Levison also previously told GWDN that despite raising more than $100 million since its founding in 2004, CardioDx is not yet eyeing an IPO, but will instead focus on increasing adoption of its Corus CAD test and developing other tests in its pipeline.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.